Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd.    4523   JP3160400002


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Biogen, Eisai revive plans for Alzheimer's drug, surprising market

share with twitter share with LinkedIn share with facebook
share via e-mail
10/23/2019 | 01:45am EST
A sign marks a Biogen facility in Cambridge

(Reuters) - Biogen Inc revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients.

The drugmaker's shares soared 27% in New York trading, recouping almost all of the $18 billion it lost when it said in March it was abandoning the two studies. Shares in Eisai Co, Biogen's Japanese partner in the drug, were quoted up 18% to the daily limit high of 6,534 yen in Tokyo trading.

The field of experimental Alzheimer's treatments is littered with high-profile failures, with many major drugmakers abandoning the race to develop a medicine for a disease that makes up 60%-70% of an estimated 50 million dementia cases globally.

Any medicine that effectively treats the disease is likely to become one of the world's top-selling drugs and could be transformative for Biogen, which is facing multiple challenges over its product pipeline.

Filing with U.S. regulators could "potentially bring back to life a drug that had been completely left for dead," RBC Capital Markets analyst Brian Abrahams wrote in a note.

"The viability of such a filing is unknown, given the mixed results - in our view, Biogen is somewhat desperate for growth drivers ... so a change in narrative is badly needed."

Biogen and Eisai decided to end the two late-stage trials of aducanumab in March when a so-called "futility analysis" revealed the trials had little hope of succeeding.

The failure spurred demands on Wall Street for the company to spend more on acquisitions, as its mainstay multiple-sclerosis franchise faced patent challenges and its newer muscle-wasting disorder treatment, Spinraza, faced competition from Switzerland's Novartis.


Biogen said on Tuesday more data had become available after the two studies were discontinued, resulting in new analysis that showed one of the trials met the main goal, while the other did not.

Results from patients in the failed second trial who had received high doses also supported the findings of the first, it added. Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation and language.

Biogen said it had met with the Food and Drug Administration twice, once in June and again on Monday to discuss the data.

"They (FDA) thought it was reasonable for us to submit an application for approval," said Chief Medical Officer Alfred Sandrock, who earlier this month became the company's R&D head.

Credit Suisse analyst Fumiyoshi Sakai said the new datasets would be presented at clinical trials meetings in early December. FDA approval was not guaranteed, and investors and analysts would remain cautious "until we see a real product," he said.

The company said it planned to submit a marketing application for aducanumab in early 2020 based on the discussions.

Baird analyst Brian Skorney said he believed FDA approval for aducanumab was highly unlikely and predicted Biogen would have an uphill task to convince regulators that the results were more than random chance.

Aducanumab works on the hypothesis that removing deposits of amyloid, a type of plaque, from the brain of patients in the early stages of the disease could stave off its ravages, which include loss of memory and the inability to care for oneself.

Biogen executives on a conference call said the results from the new analysis were positive for another Alzheimer's drug, BAN2401, which works on a similar principal and is also being jointly developed along with Eisai.

The company also reported a better-than-expected third-quarter profit, helped by higher demand for rare muscle disease drug, Spinraza. (http://bit.ly/2N0C8ed)

Shares in the company, which had lost 25.7% of its value this year as of Monday's close, rose 27% to $284.

(Reporting by Ankur Banerjee, Manas Mishra and Trisha Roy in Bengaluru; Rocky Swift in Tokyo; Editing by Bernard Orr and Stephen Coates)

By Manas Mishra and Trisha Roy

Stocks treated in this article : Biogen Inc., Eisai Co., Ltd., Novartis
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 0.99% 285.43 Delayed Quote.-5.15%
EISAI CO., LTD. 3.31% 7686 End-of-day quote.-7.33%
NOVARTIS 0.34% 89.5 Delayed Quote.20.08%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EISAI CO., LTD.
12:54aEISAI : Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan
11/13EISAI : Launches First Amazon Alexa Skill Designed to Engage with Those Impacted..
11/04EISAI : Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibito..
11/01EISAI : Supports relief efforts for typhoon hagibis
10/30EISAI CO., LTD. : Half-year results
10/23Biogen, Eisai revive plans for Alzheimer's drug, surprising market
10/22EISAI : Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Bas..
10/22BIOGEN : Up 40% Premarket on Revived Alzheimer's Drug
10/16EISAI : New drug approval for fycompa for adjunctive treatment of partial onset ..
10/15EISAI : New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset ..
More news
Financials (JPY)
Sales 2020 682 B
EBIT 2020 113 B
Net income 2020 82 015 M
Finance 2020 153 B
Yield 2020 2,05%
P/E ratio 2020 26,8x
P/E ratio 2021 29,1x
EV / Sales2020 2,98x
EV / Sales2021 2,92x
Capitalization 2 183 B
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 14
Average target price 8 470,83  JPY
Last Close Price 7 686,00  JPY
Spread / Highest target 95,2%
Spread / Average Target 10,2%
Spread / Lowest Target -41,5%
EPS Revisions
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Director
Yutaka Tsuchiya Director
Hirokazu Kanai Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD.-7.33%20 295
JOHNSON & JOHNSON4.48%354 829
ROCHE HOLDING AG24.03%260 464
MERCK AND COMPANY10.78%215 518
PFIZER-13.72%208 415
NOVARTIS20.08%204 021